Group 1 - The core viewpoint indicates a decline in Hong Kong's innovative pharmaceutical stocks, with notable drops in companies such as CSPC Pharmaceutical, which fell over 8%, and Innovent Biologics, which dropped over 5% [1] - Multiple Hong Kong innovative pharmaceutical ETFs also experienced declines, with losses exceeding 3% [1] Group 2 - Specific ETF performance shows that the Hong Kong Innovative Drug ETF (code: 513120) decreased by 3.93%, closing at 1.418, while the Hong Kong Innovative Drug 50 ETF (code: 513780) fell by 3.81%, closing at 1.819 [2] - Analysts believe that domestic medical insurance policy support and overseas value recognition will sustain the ongoing trend of Chinese innovative pharmaceuticals, with China projected to become a core procurement area by 2025 [2] - The pressure from multinational corporations facing "patent cliffs" necessitates the search for quality assets, and China's high R&D cost-effectiveness and increasing overseas recognition are driving the trend of innovation going global [2]
港股创新药概念股走低，多只港股创新药相关ETF跌超3%
Mei Ri Jing Ji Xin Wen·2025-08-07 02:45